Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of DPX-Survivac with or without low-dose cyclophosphamide in primary glioblastoma during standard-of-care therapy
2013-005387-25Phase 2Active
- Sponsor
- Sapienza
- Start
- Jan 2014
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of maveropepimut-S and cyclophosphamide in glioblastoma (GBM) (2 arms), sponsored by Sapienza. Primary endpoint: Activation of immune response. Started Jan 2014; status: active.
02
Drugs
maveropepimut-Scyclophosphamide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2013-005387-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005387-25.